Hypoxia and hypoxia inducible factors in tumor metabolism

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 263-267

  Zeng, Wen ^a,b   Liu, Peiyi ^a   Pan, Weimin ^c   Singh, Shree Ram ^d   Wei, Yiyong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Xi an Physical Education University   (China)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; HIFs; Hypoxia; Metabolism; Tumor; Tumor microenvironment

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; GLUCOSE;

AMINO ACID METABOLISM; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL METABOLISM; CELL SURVIVAL; CITRIC ACID CYCLE; DNA DAMAGE; DNA REPAIR; ENERGY YIELD; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; LIPID METABOLISM; METABOLIC REGULATION; METASTASIS; MITOCHONDRION; NONHUMAN; SHORT SURVEY; TISSUE METABOLISM; TREATMENT RESPONSE; TUMOR CELL; TUMOR INVASION; TUMOR METABOLISM; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; CELL HYPOXIA; ENERGY METABOLISM; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY;

APOPTOSIS; CELL HYPOXIA; CITRIC ACID CYCLE; DNA REPAIR; ENERGY METABOLISM; GLUCOSE; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; LIPID METABOLISM; MITOCHONDRIA; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84920123315     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.032     Document Type: Review

References (71)

1. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58:1408-1416.
2. Dasu A., Toma-Dasu I., Karlsson M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys. Med. Biol. 2003, 48:2829-2842.
3. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 1955, 9:539-549.
4. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8:705-713.
5. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
6. Germain S., Monnot C., Muller L., Eichmann A. Hypoxia-driven angiogenesis: role of tip cells and extracellular matrix scaffolding. Curr. Opin. Hematol. 2010, 17:245-251.
7. 2 sensing. Science 2001, 292:464-468.
8. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5:343-354.
9. 2 tension. Am. J. Physiol. 1996, 271:C1172-C1180.
10. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12:149-162.
11. Zeng W., Wan R., Zheng Y., Singh S.R., Wei Y. Hypoxia, stem cells and bone tumor. Cancer Lett. 2011, 313:129-136.
12. Svastova E., Hulikova A., Rafajova M., Zat'ovicova M., Gibadulinova A., Casini A., Cecchi A., Scozzafava A., Supuran C.T., Pastorek J., Pastorekova S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577:439-445.
13. Brahimi-Horn M.C., Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int. Rev. Cytol. 2005, 242:157-213.
14. Lu C.W., Lin S.C., Chen K.F., Lai Y.Y., Tsai S.J. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J. Biol. Chem. 2008, 283:28106-28114.
15. Favaro E., Ramachandran A., McCormick R., Gee H., Blancher C., Crosby M., Devlin C., Blick C., Buffa F., Li J.L., Vojnovic B., Pires das Neves R., Glazer P., Iborra F., Ivan M., Ragoussis J., Harris A.L., MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU PloS One 2010, 5:e10345.
16. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24:68-72.
17. Kaelin W.G. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:335-345.
18. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
19. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
20. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., Giaccia A.J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003, 22:5907-5914.
21. Racker E., Spector M. Warburg effect revisited: merger of biochemistry and molecular biology. Science 1981, 213:303-307.
22. Lum J.J., Bui T., Gruber M., Gordan J.D., DeBerardinis R.J., Covello K.L., Simon M.C., Thompson C.B. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007, 21:1037-1049.
23. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol. 2007, 19:223-229.
24. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
25. Brunelle J.K., Bell E.L., Quesada N.M., Vercauteren K., Tiranti V., Zeviani M., Scarpulla R.C., Chandel N.S. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 2005, 1:409-414.
26. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
27. de la Torre A.J., Rogoff D., White P.C. P53 and cellular glucose uptake. Endocr. Res. 2013, 38:32-39.
28. Zhang X.D., Qin Z.H., Wang J. The role of p53 in cell metabolism. Acta Pharmacol. Sin. 2010, 31:1208-1212.
29. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., Dalla-Favera R., Dang C.V. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 1997, 94:6658-6663.
30. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-3899.
31. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., Hwang P.M. P53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
32. Carracedo A., Cantley L.C., Pandolfi P.P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 2013, 13:227-232.
33. Rankin E.B., Higgins D.F., Walisser J.A., Johnson R.S., Bradfield C.A., Haase V.H. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol. Cell. Biol. 2005, 25:3163-3172.
34. Rankin E.B., Rha J., Selak M.A., Unger T.L., Keith B., Liu Q., Haase V.H. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol. Cell. Biol. 2009, 29:4527-4538.
35. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. USA 2002, 99:10231-10233.
36. Kannagi R., Yin J., Miyazaki K., Izawa M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomori's concepts revisited. Biochim. Biophys. Acta 2008, 1780:525-531.
37. Kannagi R., Sakuma K., Miyazaki K., Lim K.T., Yusa A., Yin J., Izawa M. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. Cancer Sci. 2010, 101:586-593.
38. Yin J., Miyazaki K., Shaner R.L., Merrill A.H., Kannagi R. Altered sphingolipid metabolism induced by tumor hypoxia - new vistas in glycolipid tumor markers. FEBS Lett. 2010, 584:1872-1878.
39. Chan N., Milosevic M., Bristow R.G. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol. 2007, 3:329-341.
40. Bindra R.S., Crosby M.E., Glazer P.M. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007, 26:249-260.
41. Bristow R.G., Hill R.P. Hypoxia and metabolism, hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 2008, 8:180-192.
42. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-4515.
43. Terris D.J., Ho E.Y., Ibrahim H.Z., Dorie M.J., Kovacs M.S., Le Q.T., Koong A.C., Pinto H.A., Brown J.M. Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay. Arch. Otolaryngol. Head Neck Surgery 2002, 128:698-702.
44. Hammond E.M., Dorie M.J., Giaccia A.J. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 2003, 278:12207-12213.
45. Bell E.L., Chandel N.S. Mitochondrial oxygen sensing: regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species. Essays Biochem. 2007, 43:17-27.
46. Zhu Y., McAvoy S., Kuhn R., Smith D.I. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 2006, 25:2901-2908.
47. Bacon A.L., Harris A.L. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann. Med. 2004, 36:530-539.
48. Koritzinsky M., Magagnin M.G., van den Beucken T., Seigneuric R., Savelkouls K., Dostie J., Pyronnet S., Kaufman R.J., Weppler S.A., Voncken J.W., Lambin P., Koumenis C., Sonenberg N., Wouters B.G. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J. 2006, 25:1114-1125.
49. Favaro E., Nardo G., Persano L., Masiero M., Moserle L., Zamarchi R., Rossi E., Esposito G., Plebani M., Sattler U., Mann T., Mueller-Klieser W., Ciminale V., Amadori A., Indraccolo S. Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am. J. Pathol. 2008, 173:1186-1201.
50. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
51. Gordan J.D., Bertout J.A., Hu C.J., Diehl J.A., Simon M.C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007, 11:335-347.
52. Brown J.M. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain memorial award lecture. Cancer Res. 1999, 59:5863-5870.
53. Kizaka-Kondoh S., Inoue M., Harada H., Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 2003, 94:1021-1028.
54. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
55. Milane L., Duan Z., Amiji M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int. 2011, 11:3.
56. Harris A.L., Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 1992, 31:205-213.
57. Zhang D., Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010, 6:527-537.
58. Skovsgaard T. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem. Pharmacol. 1977, 26:215-222.
59. Shen J., Hughes C., Chao C., Cai J., Bartels C., Gessner T., Subjeck J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc. Natl. Acad. Sci. USA 1987, 84:3278-3282.
60. Meijer T.W., Kaanders J.H., Span P.N., Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin. Cancer Res. 2012, 18:5585-5594.
61. Gillies R.J., Robey I., Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 2008, 49(Suppl 2):24S-42S.
62. Ganapathy V., Thangaraju M., Prasad P.D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009, 121:29-40.
63. Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 2013, 123:3664-3671.
64. Zhao Y., Butler E.B., Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013, 4:e532.
65. Cairns R.A., Papandreou I., Sutphin P.D., Denko N.C. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc. Natl. Acad. Sci. USA 2007, 104:9445-9450.
66. Baker L.C., Boult J.K., Walker-Samuel S., Chung Y.L., Jamin Y., Ashcroft M., Robinson S.P. The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br. J. Cancer 2012, 106:1638-1647.
67. Zhao T., Zhu Y., Morinibu A., Kobayashi M., Shinomiya K., Itasaka S., Yoshimura M., Guo G., Hiraoka M., Harada H. HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Sci. Rep. 2014, 4:3793.
68. Schulze A., Harris A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012, 491:364-373.
69. Mucaj V., Shay J.E., Simon M.C. Effects of hypoxia and HIFs on cancer metabolism. Int. J. Hematol. 2012, 95:464-470.
70. Lu H., Li X., Luo Z., Liu J., Fan Z. Cetuximab reverses the Warburg effect by inhibiting HIF-1regulated LDH-A. Mol. Cancer Ther. 2013, 12:2187-2199.
71. Hu Y., Liu J., Huang H. Recent agents targeting HIF-1α for cancer therapy. J. Cell Biochem. 2013, 114(3):498-509.